Bio-Rad Laboratories (NYSE: BIO) reports death of co-founder Alice N. Schwartz at 99

Rhea-AI Filing Summary

Bio-Rad Laboratories, Inc. reported the passing of its co-founder and Director Emeritus, Alice N. Schwartz, under a Regulation FD disclosure. The company announced that she died on September 25, 2025, at the age of 99. This reflects a significant moment in the company’s history given her foundational role, but the disclosure does not describe any immediate operational or financial impacts.

The announcement was made on September 29, 2025, and a related press release was provided as an exhibit to the report. The company states that this information is being furnished, not filed, which limits how it is treated under securities law liability provisions.

0000012208false00000122082025-09-292025-09-290000012208us-gaap:CommonClassAMember2025-09-292025-09-290000012208us-gaap:CommonClassBMember2025-09-292025-09-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report:   September 29, 2025

(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-07928

Delaware						94-1381833
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

1000 Alfred Nobel Dr.

Hercules, California 94547

(Address of principal executive offices, including zip code)

(510)724-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, Par Value $0.0001 per share

BIO

New York Stock Exchange

Class B Common Stock, Par Value $0.0001 per share

BIO.B

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

			Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.						☐

Item 7.01 Regulation FD Disclosure.

On September 29, 2025, Bio-Rad Laboratories, Inc. (the “Company”) announced that Alice N. Schwartz, the Company’s co-founder and Director Emeritus, passed away on September 25, 2025, at the age of 99. A copy of the press release is furnished with this report as Exhibit 99.1.

The information contained in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number						Description
99.1						Press release dated September 29, 2025
104.1						Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-RAD LABORATORIES, INC.

Date:

September 30, 2025

By:

/s/ Courtney C. Enloe

Courtney C. Enloe

Executive Vice President, General Counsel & Secretary

FAQ

What did Bio-Rad Laboratories (BIO) disclose in this 8-K?

Bio-Rad Laboratories disclosed that its co-founder and Director Emeritus, Alice N. Schwartz, passed away on September 25, 2025, at the age of 99. The company furnished a related press release as an exhibit.

Who was Alice N. Schwartz in relation to Bio-Rad Laboratories (BIO)?

Alice N. Schwartz was a co-founder of Bio-Rad Laboratories and served as Director Emeritus. Her passing is a notable event in the company’s history, though no governance or management changes are described in this disclosure.

When did Bio-Rad announce the passing of its co-founder?

The company announced the passing of Alice N. Schwartz on September 29, 2025. The report states that she passed away on September 25, 2025, and includes a press release dated September 29, 2025 as Exhibit 99.1.

Does this Bio-Rad 8-K include new financial or earnings information?

No. The 8-K focuses on the passing of Alice N. Schwartz and the furnishing of a related press release. It does not provide financial results, earnings data, or describe major transactions.

How is the information in this Bio-Rad (BIO) 8-K treated under securities laws?

The company states that the information in Item 7.01 is being furnished, not filed, under the Exchange Act. As a result, it is not subject to the liabilities of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated.

What exhibits are included with this Bio-Rad Laboratories 8-K?

The 8-K lists Exhibit 99.1, a press release dated September 29, 2025, and Exhibit 104.1, the cover page interactive data file with XBRL tags embedded within the Inline XBRL document.